Oncology Central

Osteoblastoma genetic marker shows promise for identifying aggressive tumors

Researchers at the Wellcome Sanger Institute (London, UK) have discovered a genetic mutation that distinguishes between benign osteoblastoma tumors and aggressive osteosarcoma tumors. This could offer faster diagnosis and earlier treatment for patients with the disease.
To view restricted content, please:



News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.